Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9126-9131

  Liu, Shanling ^a,b   Wang, He ^b   Yang, Zhonghui ^a   Kon, Takashi ^a   Zhu, Jiangao ^a   Cao, Yiting ^a   Li, Fang ^a   Kirkpatrick, John ^a   Nicchitta, Christopher V ^a   Li, Chuan Yuan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GLUCOSE REGULATED PROTEIN; GLYCOPROTEIN GP 96; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; GENE; GRP94 GENE; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; VACCINATION;

ADENOVIRIDAE; ANIMALS; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; HSP70 HEAT-SHOCK PROTEINS; INTERFERON TYPE II; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; VACCINATION;

EID: 27144559140     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0945     Document Type: Article

References (15)

1. Blachere NE, Li Z, Chandawarkar R, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997;186:1315-22.
2. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20.
3. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20:4169-80.
4. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88:232-8.
5. Mazzaferro V Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9:3235-45.
6. Ishii T, Udono H, Yamano T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999;162:1303-9.
7. Wallin RP, Lundqvist A, More SH, et al. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002;23:130-5.
8. Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 2002;196:1447-59.
9. Nicchitta CV, Carrick DM, Baker-Lepain JC. The messenger and the message: gp96 (GRP94)-peptide interactions in cellular immunity. Cell Stress Chaperones 2004;9:325-31.
10. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13.
11. + T cell Th1 cytokine production in vivo. J Immunol 2004;172:4195-203.
12. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertion or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994;91:8802-6.
13. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995;3:207-20.
14. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-92.
15. Taguchi T, McGhee JR, Coffman RL, et al. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J Immunol Methods 1990;128:65-73.